| Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial JR Biesiekierski, ED Newnham, PM Irving, JS Barrett, M Haines, ... Official journal of the American College of Gastroenterology| ACG 106 (3 …, 2011 | 1098 | 2011 |
| Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome DK Ong, SB Mitchell, JS Barrett, SJ Shepherd, PM Irving, JR Biesiekierski, ... Journal of gastroenterology and hepatology 25 (8), 1366-1373, 2010 | 788 | 2010 |
| Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndrome HM Staudacher, MCE Lomer, JL Anderson, JS Barrett, JG Muir, PM Irving, ... The Journal of nutrition 142 (8), 1510-1518, 2012 | 776 | 2012 |
| Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study NA Kennedy, GA Heap, HD Green, B Hamilton, C Bewshea, GJ Walker, ... The lancet Gastroenterology & hepatology 4 (5), 341-353, 2019 | 666 | 2019 |
| Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome HM Staudacher, K Whelan, PM Irving, MCE Lomer Journal of human nutrition and dietetics 24 (5), 487-495, 2011 | 656 | 2011 |
| Dietary poorly absorbed, short‐chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon JS Barrett, RB Gearry, JG Muir, PM Irving, R Rose, O Rosella, ML Haines, ... Alimentary pharmacology & therapeutics 31 (8), 874-882, 2010 | 538 | 2010 |
| A diet low in FODMAPs reduces symptoms in patients with irritable bowel syndrome and a probiotic restores bifidobacterium species: a randomized controlled trial HM Staudacher, MCE Lomer, FM Farquharson, P Louis, F Fava, ... Gastroenterology 153 (4), 936-947, 2017 | 479 | 2017 |
| Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease—a pilot study RB Gearry, PM Irving, JS Barrett, DM Nathan, SJ Shepherd, PR Gibson Journal of Crohn's and Colitis 3 (1), 8-14, 2009 | 422 | 2009 |
| Epithelia use butyrophilin-like molecules to shape organ-specific γδ T cell compartments RDM Barros, NA Roberts, RJ Dart, P Vantourout, A Jandke, ... Cell 167 (1), 203-218. e17, 2016 | 365 | 2016 |
| HLA-DQA1* 05 carriage associated with development of anti-drug antibodies to infliximab and adalimumab in patients with Crohn’s disease A Sazonovs, NA Kennedy, L Moutsianas, GA Heap, DL Rice, M Reppell, ... Gastroenterology 158 (1), 189-199, 2020 | 362 | 2020 |
| Effects of low FODMAP diet on symptoms, fecal microbiome, and markers of inflammation in patients with quiescent inflammatory bowel disease in a randomized trial SR Cox, JO Lindsay, S Fromentin, AJ Stagg, NE McCarthy, N Galleron, ... Gastroenterology 158 (1), 176-188. e7, 2020 | 343 | 2020 |
| Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases K Papamichael, AS Cheifetz, GY Melmed, PM Irving, NV Casteele, ... Clinical Gastroenterology and Hepatology 17 (9), 1655-1668. e3, 2019 | 330 | 2019 |
| Mechanisms and efficacy of dietary FODMAP restriction in IBS HM Staudacher, PM Irving, MCE Lomer, K Whelan Nature reviews Gastroenterology & hepatology 11 (4), 256-266, 2014 | 329 | 2014 |
| British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic NA Kennedy, GR Jones, CA Lamb, R Appleby, I Arnott, RM Beattie, ... Gut 69 (6), 984-990, 2020 | 300 | 2020 |
| Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD NA Kennedy, S Lin, JR Goodhand, N Chanchlani, B Hamilton, ... Gut 70 (10), 1884-1893, 2021 | 274 | 2021 |
| The γδTCR combines innate immunity with adaptive immunity by utilizing spatially distinct regions for agonist selection and antigen responsiveness D Melandri, I Zlatareva, RAG Chaleil, RJ Dart, A Chancellor, ... Nature immunology 19 (12), 1352-1365, 2018 | 238 | 2018 |
| Long‐term impact of the low‐FODMAP diet on gastrointestinal symptoms, dietary intake, patient acceptability, and healthcare utilization in irritable bowel syndrome M O'keeffe, C Jansen, L Martin, M Williams, L Seamark, HM Staudacher, ... Neurogastroenterology & Motility 30 (1), e13154, 2018 | 230 | 2018 |
| Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's disease JB Canavan, C Scottà, A Vossenkämper, R Goldberg, MJ Elder, I Shoval, ... Gut 65 (4), 584-594, 2016 | 226 | 2016 |
| HLA-DQA1–HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants GA Heap, MN Weedon, CM Bewshea, A Singh, M Chen, JB Satchwell, ... Nature genetics 46 (10), 1131-1134, 2014 | 224 | 2014 |
| Fermentable carbohydrate restriction (low FODMAP diet) in clinical practice improves functional gastrointestinal symptoms in patients with inflammatory bowel disease AC Prince, CE Myers, T Joyce, P Irving, M Lomer, K Whelan Inflammatory bowel diseases 22 (5), 1129-1136, 2016 | 221 | 2016 |
